AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +75

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

📈 ABBV stock rose approximately 5% after reporting strong Q1 2026 results that beat earnings and revenue estimates.

🚀 Earnings per share increased 7.7% year-over-year while revenues grew 10.3% on an operational basis.

💰 The company raised its full-year 2026 EPS guidance from $13.96-$14.16 to a new range of $14.08-$14.28.

📉 Full-year 2026 revenue guidance was elevated from $67 billion to $67.3 billion following the robust quarter.

💊 Skyrizi and Rinvoq, key immunology drugs, significantly outperformed estimates with combined Q1 2025 sales of $6.6 billion.

🔮 AbbVie projects combined Skyrizi and Rinvoq sales to exceed $31 billion in 2026, representing over 20% growth.

💉 New regulatory approvals are imminent for Rinvoq, including potential indications for vitiligo, alopecia areata, hidradenitis suppurativa, and systemic lupus erythematosus.

🧠 Neuroscience sales surged 24.3% to $2.88 billion in Q1, driven by Botox Therapeutic, Vraylar, and new migraine medications.

⏳ Parkinson's drug Vyalev showed encouraging initial international uptake with expectations to reach blockbuster status in 2026.

🧬 The company maintains a robust oncology franchise featuring Imbruvica and Venclexta despite a slight 3% Q1 sales decline.

💉 A substantial pipeline is expected throughout 2026 with key readouts for candidates targeting metastatic colorectal cancer and multiple myeloma.

🤝 Management indicated strong financial capacity to continue the acquisition strategy in immunology, oncology, and neuroscience.

⚠️ AbbVie anticipates low single-digit pricing headwinds for Skyrizi and Rinvoq throughout 2026 and subsequent years.

🦾 Competitive pressure is mounting from J&J's new oral psoriasis pill Icotyde, though the company remains confident in navigating this challenge.

📉 Humira sales continue to decline due to biosimilar erosion, with a projected drop of around 50% in 2025 continuing into 2026.

💇 Aesthetics unit sales have softened due to macroeconomic challenges, with global projections expected to remain flat at $5 billion for 2026.

Bullish Signals
  • AbbVie reported robust Q1 2026 results with earnings rising 7.7% year-over-year and revenues growing 10.3% on an operational basis.
  • The company raised its full-year EPS guidance from a range of $13.96-$14.16 to $14.08-$14.28, signaling strong confidence in future performance.
  • Guidance for 2026 total revenue was increased to $67.3 billion, exceeding the previous expectation of $67 billion.
  • Key immunology drugs Skyrizi and Rinvoq combined generated $6.6 billion in Q1 sales and are projected to deliver more than 20% growth in 2026 with expected combined sales exceeding $31 billion.
  • Rinvoq has potential for five new indications, including approvals expected for vitiligo and alopecia areata in 2026/early 2027, which could add roughly $2 billion to peak-year sales.
  • AbbVie's neuroscience portfolio showed strength with sales increasing 24.3% to $2.88 billion, driven by growth in Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, and the new Parkinson's drug Vyalev.
  • The Parkinson's disease franchise is viewed as a key growth driver with over $5 billion in peak sales potential for Vyalev and tavapadon.
  • AbbVie has a robust pipeline with expected data readouts for lutikizumab, Temab-A, and etentamig, alongside important regulatory submissions throughout 2026.
  • Management indicated significant financial capacity to pursue early and late-stage opportunities through M&A deals in immunology, oncology, and neuroscience.
  • AbbVie is evaluating Skyrizi-based combination regimens with candidates like ABBV-382 and ABBV-701 to create best-in-class durable remission therapies in IBD.
Risk Factors
  • AbbVie expects a low single-digit pricing headwind for its two flagship immunology drugs, Skyrizi and Rinvoq, in 2026 and beyond.
  • Competitive pressure has intensified with the launch of J&J's Icotyde oral pill for plaque psoriasis, which poses a direct threat to Skyrizi's prescription trends.
  • Sales of the company's largest revenue driver, Humira, have plummeted by approximately 50% in 2025 due to biosimilar erosion and continued exclusivity loss.
  • The Aesthetics division is facing soft sales driven by macroeconomic headwinds, with global aesthetics sales projected to be flat at $5 billion in 2026 despite new Botox growth.
  • Juvederm sales are expected to decline further as the company faces continued headwinds in key dermal filler markets.
  • Oncology sales have recently declined by 3% to $1.63 billion in Q1, indicating potential stagnation or pressure within that franchise.
Full Analysis
AbbVie (ABBV) shares gained approximately 5% following the release of robust first-quarter fiscal 2026 results on April 29, which beat analyst estimates for both earnings per share and sales. The company further strengthened investor confidence by raising its full-year guidance for 2026, updating earnings per share expectations from a range of $13.96–$14.16 to $14.08–$14.28, while increasing total revenue guidance from $67 billion to $67.3 billion. Both Skyrizi and Rinvoq drove strong sales performance in the quarter, exceeding estimates and contributing to a 10.3% operational revenue increase, marking a significant turnaround as the company successfully navigates the loss of exclusivity for its flagship Humira drug, which saw sales decline roughly 50% in 2025 due to biosimilar competition. The core immunology portfolio, consisting of Skyrizi and Rinvoq, generated combined first-quarter sales of $6.6 billion with expectations for over $31 billion in combined sales for 2026, representing more than 20% growth. Growth drivers include approvals in new indications such as vitiligo and alopecia areata for Rinvoq in 2026 or early 2027, alongside anticipated phase III data readouts for hidradenitis suppurativa and systemic lupus erythematosus. AbbVie acknowledges headwinds including low single-digit pricing pressure for these immunology drugs and competitive threats from J&J’s Icotyde, but maintains confidence in its ability to offset prescription trends through product differentiation and new approvals. Beyond immunology, AbbVie's neuroscience segment posted a 24.3% sales increase to $2.88 billion in Q1 2026, fueled by growth in Botox Therapeutic, Vraylar, and new migraine treatments, while the Parkinson’s disease franchise gained momentum with Vyalev on track for blockbuster status and tavapadon under review for potential approval in Q3 2026. The oncology business saw sales decline 3% to $1.63 billion as declines in Imbruvica were partially offset by new drugs, though the pipeline remains robust with upcoming data readouts for candidates like lutikizumab and etentamig. Additionally, the company has expanded its early-stage pipeline through a series of recent M&A deals in immunology, oncology, and neuroscience, leveraging financial capacity highlighted by CEO Robert Michael.